Cargando…
Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth
Proteasomes are attractive emerging targets for anti-cancer therapies. Auranofin (Aur), a gold-containing compound clinically used to treat rheumatic arthritis, was recently approved by US Food and Drug Administration for Phase II clinical trial to treat cancer but its anti-cancer mechanism is poorl...
Autores principales: | Liu, Ningning, Li, Xiaofen, Huang, Hongbiao, Zhao, Chong, Liao, Siyan, Yang, Changshan, Liu, Shouting, Song, Wenbin, Lu, Xiaoyu, Lan, Xiaoying, Chen, Xin, Yi, Songgang, Xu, Li, Jiang, Lili, Zhao, Canguo, Dong, Xiaoxian, Zhou, Ping, Li, Shujue, Wang, Shunqing, Shi, Xianping, Dou, Ping Q., Wang, Xuejun, Liu, Jinbao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4170648/ https://www.ncbi.nlm.nih.gov/pubmed/24977961 |
Ejemplares similares
-
A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases
por: Liu, Ningning, et al.
Publicado: (2014) -
Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo
por: Huang, Hongbiao, et al.
Publicado: (2015) -
Intracellular ATP Concentration Contributes to the Cytotoxic and Cytoprotective Effects of Adenosine
por: Li, Shujue, et al.
Publicado: (2013) -
A microRNA-mediated decrease in eukaryotic initiation factor 2α promotes cell survival during PS-341 treatment
por: Jiang, Lili, et al.
Publicado: (2016) -
Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms
por: Chen, Xin, et al.
Publicado: (2014)